Projects

• Ongoing projects

PNRR-III-C9-2022-I8-186 (FIBROTHERA)

Project Title: Targeting Cardiac Fibrosis in Heart Failure; Challenges and Potential Solutions Based on ncRNA Therapeutics

Implementation period: 18.07.2023 – 31.06.2026

Abstract: FibroThera aims to fight against myocardial infarction (MI)-induced heart failure, a major human health problem with high socio-economic implications. In this project, we will abandon the traditional focus on protein-coding genes and explore the noncoding RNA-mediated regulatory pathways. The FibroThera concept is based on the assumption that identifying the ncRNA specifically involved in MI-induced heart failure will increase the probability of finding new druggable therapeutic targets with clinical applicability, which can improve the quality of life in ischemic heart disease patients. FibroThera will characterize the dynamics of cells contributing to fibrosis during post-MI cardiac repair and will propose solutions for limiting the adverse remodelling after MI.

• Completed projects

1. PN-III-P4-ID-PCE-2020-1340 (Inf-OLD). Title: Fundamental mechanisms of post-infarction remodeling in old heart at fibroblast population level. Implementation period: 2021 – 2023.
2. PN-III-P1-1.1-TE-2019-1893 (210-HINT). Title: MIR-210 genomic locus at the overlap between hypoxia signalling and inflammatory networks. Implementation period: 2021 – 2022.
3. PN-III-P4-ID-PCCF-2016-0172 (INNATE-MI). Title: Targeting innate immune mechanisms to improve risk stratification and to identify future therapeutic options in myocardial infarction. Implementation period: 2018 – 2022.
4. PN-III-P1-1.1-PD-2016-1903 (OXI-SCENARIO). Title: Interference with hypoxia-signaling pathways in mesenchymal stem cells prior to transplantation as a strategy to enhance myocardial recovery post infarction. Implementation period: 2018 – 2020.
5. POC-A.1-A.1.1.4-E-2015, ID: P_37_668 (DIABETER). Title: Research, technological development and innovation (RDI) in support of economic competitiveness and business development. Implementation period: 2016 – 2020.
6. (EXPERT). Title: Exploring new pathways in age-related heart diseases. Implementation period: 2017 – 2020.
7. PN-III-P2-2.1-PED-2016-1881 (CO-SUSTAIN). Title: Consolidating the subcutaneous transplantation of MSC as a warranted therapy for myocardial infarction. Implementation period: 2017 – 2018.